What is Pimitespib?

Pimitespib (Pimitespib) is the first heat shock protein 90 (HSP90) inhibitor approved in Japan. It is suitable for the treatment of gastrointestinal stromal tumors (GIST) that have progressed after treatment with imatinib (Imatinib), sunitinib and regorafenib. Gastrointestinal stromal tumor is a type of cancer found in the gastrointestinal tract, and those cancers that are considered "advanced" have not responded to other treatments and have spread to other parts of the body.

Pimoteb works differently than other cancer drug treatments by inhibiting a protein called heat shock protein 90, which prevents cancer cells from developing and growing. Pimetibib is taken orally. A study of Japanese patients with advanced gastrointestinal stromal tumors showed that those who received pimetibib took longer for their cancer to progress and for longer to survive compared with those who did not receive the drug.

These studies also found that pimetibib was not associated with serious side effects, although diarrhea occurred frequently. Some patients developed ocular disease that could be controlled by interrupting or discontinuing pimoteb therapy. Pimetib is also being studied to treat other cancers, either alone or in combination with other anticancer drugs.

For patients with advanced gastrointestinal stromal tumors, there are very few treatments available, so pimotebib is an important new option for these patients in Japan. If the results of ongoing studies are positive, pimetibib may become a treatment option for a wider range of cancer patients in the future. Pimetibi is not marketed in China, and it has been on the market overseas for a short time, and there is little information about its price and other related information.